Arcus Biosciences (NYSE:RCUS) Earns Buy Rating from Analysts at SunTrust Banks

SunTrust Banks initiated coverage on shares of Arcus Biosciences (NYSE:RCUS) in a research note issued to investors on Tuesday morning, Briefing.com Automated Import reports. The firm issued a buy rating and a $20.00 price target on the stock.

Several other analysts have also recently commented on the stock. Mizuho reiterated a buy rating and set a $22.00 target price on shares of Arcus Biosciences in a research report on Monday, November 11th. Zacks Investment Research cut shares of Arcus Biosciences from a buy rating to a hold rating in a research report on Thursday, November 7th. Finally, ValuEngine upgraded shares of Arcus Biosciences from a hold rating to a buy rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $17.35.

Shares of Arcus Biosciences stock traded down $0.32 on Tuesday, hitting $7.65. 72,356 shares of the company’s stock traded hands, compared to its average volume of 248,848. The firm’s 50-day moving average price is $8.29 and its two-hundred day moving average price is $8.45. The stock has a market capitalization of $366.41 million, a PE ratio of -5.35 and a beta of 0.99. Arcus Biosciences has a one year low of $6.30 and a one year high of $13.77.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The business had revenue of $1.75 million for the quarter, compared to the consensus estimate of $1.34 million. Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. Research analysts expect that Arcus Biosciences will post -2.19 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Aperio Group LLC acquired a new position in Arcus Biosciences in the 2nd quarter worth $32,000. Meeder Asset Management Inc. boosted its stake in Arcus Biosciences by 672.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock worth $46,000 after purchasing an additional 4,300 shares during the period. Susquehanna International Group LLP acquired a new position in Arcus Biosciences in the 2nd quarter worth $119,000. Athanor Capital LP acquired a new position in Arcus Biosciences in the 2nd quarter worth $126,000. Finally, Russell Investments Group Ltd. acquired a new position in Arcus Biosciences in the 2nd quarter worth $128,000. 46.83% of the stock is owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Featured Article: How to Invest in the Dividend Aristocrat Index

Analyst Recommendations for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.